$398 Million is the total value of DAFNA Capital Management LLC's 87 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| STXS | STEREOTAXIS INC | $84,819,000 | +15.2% | 13,680,554 | 0.0% | 21.33% | +9.2% | |
| BPMC | BLUEPRINT MEDICINES CORP | $22,162,000 | +4.2% | 206,911 | 0.0% | 5.57% | -1.3% | |
| ARNA | ARENA PHARMACEUTICALS INC | $11,117,000 | +56.1% | 119,615 | 0.0% | 2.80% | +47.9% | |
| IDYA | IDEAYA BIOSCIENCES INC | $10,876,000 | -7.3% | 460,061 | 0.0% | 2.74% | -12.1% | |
| NRIX | NURIX THERAPEUTICS INC | $8,868,000 | -3.4% | 306,320 | 0.0% | 2.23% | -8.4% | |
| MORF | MORPHIC HLDG INC | $8,598,000 | -16.3% | 181,467 | 0.0% | 2.16% | -20.7% | |
| SAGE | SAGE THERAPEUTICS INC | $7,670,000 | -4.0% | 180,306 | 0.0% | 1.93% | -9.0% | |
| IBB | ISHARES TR NASDAQ BIOTECHetf | $6,242,000 | -5.6% | 40,900 | 0.0% | 1.57% | -10.5% | |
| ATRC | ATRICURE INC | $5,008,000 | -0.0% | 72,029 | 0.0% | 1.26% | -5.3% | |
| ARAY | ACCURAY INC | $4,492,000 | +20.8% | 941,800 | 0.0% | 1.13% | +14.5% | |
| RADIUS HEALTH INCnote 3.000% 9/0 | $3,860,000 | +6.3% | 4,000,000 | 0.0% | 0.97% | +0.8% | ||
| FSTX | F-STAR THERAPEUTICS INC | $3,483,000 | -31.4% | 693,785 | 0.0% | 0.88% | -35.0% | |
| ATHA | ATHIRA PHARMA INC | $2,098,000 | +38.9% | 160,983 | 0.0% | 0.53% | +31.7% | |
| VKTX | VIKING THERAPEUTICS INC | $2,058,000 | -26.8% | 447,400 | 0.0% | 0.52% | -30.6% | |
| AERI | AERIE PHARMACEUTICALS INC | $2,029,000 | -38.4% | 289,040 | 0.0% | 0.51% | -41.6% | |
| COGT | COGENT BIOSCIENCES INC | $1,918,000 | +2.0% | 223,554 | 0.0% | 0.48% | -3.4% | |
| KNTE | KINNATE BIOPHARMA INC | $1,886,000 | -23.1% | 106,453 | 0.0% | 0.47% | -27.1% | |
| MREO | MEREO BIOPHARMA GROUP PLCads | $1,803,000 | -33.9% | 1,126,613 | 0.0% | 0.45% | -37.3% | |
| BWAY | BRAINSWAY LTDsponsored ads | $1,540,000 | -4.5% | 200,000 | 0.0% | 0.39% | -9.6% | |
| MGNX | MACROGENICS INC | $1,445,000 | -23.3% | 90,000 | 0.0% | 0.36% | -27.4% | |
| STIM | NEURONETICS INC | $1,399,000 | -32.0% | 313,717 | 0.0% | 0.35% | -35.5% | |
| AERIE PHARMACEUTICALS INCnote 1.500%10/0 | $1,243,000 | -9.6% | 1,500,000 | 0.0% | 0.31% | -14.2% | ||
| MASI | MASIMO CORP | $878,000 | +8.1% | 3,000 | 0.0% | 0.22% | +2.8% | |
| MRSN | MERSANA THERAPEUTICS INC | $872,000 | -34.1% | 140,263 | 0.0% | 0.22% | -37.6% | |
| CGEN | COMPUGEN LTDord | $866,000 | -28.0% | 201,502 | 0.0% | 0.22% | -31.7% | |
| FIELD TRIP HEALTH LTD | $839,000 | -46.4% | 340,900 | 0.0% | 0.21% | -49.2% | ||
| ASLN | ASLAN PHARMACEUTICALS LTDads | $820,000 | -37.1% | 732,500 | 0.0% | 0.21% | -40.5% | |
| HARP | HARPOON THERAPEUTICS INC | $794,000 | -4.5% | 105,163 | 0.0% | 0.20% | -9.1% | |
| LVTX | LAVA THERAPEUTICS NV | $766,000 | -7.2% | 139,332 | 0.0% | 0.19% | -11.9% | |
| INFI | INFINITY PHARMACEUTICALS INC | $531,000 | -34.3% | 236,160 | 0.0% | 0.13% | -37.4% | |
| INGN | INOGEN INC | $510,000 | -21.1% | 15,000 | 0.0% | 0.13% | -25.1% | |
| BOLT | BOLT BIOTHERAPEUTICS INC | $490,000 | -61.3% | 100,000 | 0.0% | 0.12% | -63.4% | |
| MDGL | MADRIGAL PHARMACEUTICALS INC | $475,000 | +6.3% | 5,600 | 0.0% | 0.12% | 0.0% | |
| SRGA | SURGALIGN HOLDINGS INC | $415,000 | -34.3% | 579,710 | 0.0% | 0.10% | -38.1% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.